2023 EULAR Recommendations for Imaging in Large Vessel Vasculitis

Save

EULAR has published its expert consensus regarding the recommendations for imaging in the most common types of large vessel vasculitis (LVV) -- giant cell arteritis (GCA) and Takayasu arteritis (TAK).

Fracture Risk Quantified for Older Spondyloarthritis Patients

Save

Medicare beneficiaries with ankylosing spondylitis (AS) incur frequent bone fractures, a new study indicated, with the risk boosted by some unsurprising factors but also including one that was not expected.

15% of the World Population has Osteoarthritis

Save

The Lancet reports a new study revealing that the most common form of arthritis, osteoarthritis, affects 15% of the global population over the age of 30.

Cardiovascular Disease Precedes ANCA-associated Vasculitis

Save

A nested case–control study from the Danish Nationwide Registries finds an increased risk of cardiovascular (CV) disease in the months preceding diagnosis of ANCA-associated vasculitis (AAV).

Manifestations of Systemic Sclerosis Sine Scleroderma

Save

Systemic sclerosis (SSc) sine scleroderma is a unique and rare subset of SSc defined by the absence of skin fibrosis. An analysis of the EUSTAR database suggests systemic disease can be a problem, including interstitial lung disease (>40%) and SSc renal crisis (almost 3%). 

Mono- and Oligo- are Different (8.18.2023)

Save

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.

COSMOS: Guselkumab's Immunologic Benefits in Psoriatic Arthritis

Save

The IL-23 inhibitor guselkumab was studied in active psoriatic arthritis patients in the phase 3b COSMOS trial, and shown to be clinically effective while reducing multiple effector cytokines, including those associated with the IL-23/IL-17 pathway.

Imaging Mass Cytometry to Study Lupus Nephritis

Save

Lupus researchers from the University of Houston are reporting the first use of the powerful imaging mass cytometry to examine the kidneys of patients with systemic lupus erythematosus, as a means of diagnosing lupus nephritis in SLE patients.  LN is a severe inflammation of the kidneys and a major cause of death in lupus patients. Up to 60% of SLE patients will develop renal symptoms with 5–20% of those patients progressing to end stage kidney disease within 10 years. 

Residual Disease in Controlled Axial Spondyloarthritis

Save

Despite being in a state of remission or low disease activity state, in patients with axial spondyloarthritis, up to 42% may still have residual disease.

Stable Safety Outcomes with Abatacept

Save

The safety of abatacept was studied using patients with rheumatoid arthritis (RA) from 7 European registers, revealing safety signals on par with that previously reported with no new safety concerns. 

The Adalimumab Biosimilar Glut

Save

In 2023, three marketed biosimilars (Actemra, Stelara, Humira) had their patents expire, opening opportunities for multiple new biosimilars; but with competition comes a word salad of new drug names, confusion and nonsensical discounts.

Glucocorticoid Affects Weight, but not Blood Pressure in RA

Save

A pooled analysis of 5 randomized controlled trials (RCTs) shows that the effects of 2 years of low-dose glucocorticoid (GC) treatment in rheumatoid arthritis (RA) can significantly increase increase body weight, but not blood pressure.